Association Between HPV-16 and Head and Neck Cancer

Detection of oral human papillomavirus 16 (HPV-16) associated with an approximately 22 times higher risk for developing oropharyngeal squamous cell carcinoma.
Detection of oral human papillomavirus 16 (HPV-16) associated with an approximately 22 times higher risk for developing oropharyngeal squamous cell carcinoma.

Detection of oral human papillomavirus 16 (HPV-16) was associated with an approximately 22 times higher risk for developing oropharyngeal squamous cell carcinoma (SCC), a study published online ahead of print in JAMA Oncology has shown.1

Because there is limited data on the association between α-, β-, and γ-HPV types and the risk of head and neck SCC (HNSCC), researchers sought to prospectively examine association between α-, β-, and γ-HPV detection in the oral cavity and incident HNSCC.

For the study, researchers analyzed data from 96 650 participants of the American Cancer Society Cancer Prevention Study II Nutrition Cohort and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Of those, 132 incident cases of HNSCC were identified during a mean follow-up of 3.9 years. A total of 396 participants were selected as controls.

Results showed that HPV-16 detection in the oral cavity was associated with incident HNSCC (OR, 7.1; 95% CI: 2.2-22.6) and a positive association for oropharyngeal SCC (OR, 22.4: 95% CI, 1.8-276.7). In contrast, researchers did observe a positive association for oral cavity (OR, 4.5; 95% CI: 0.6-34.7) or laryngeal SCCs (OR, 0.11; 95% CI: 0.01-834.80).

In terms of the broader role HPVs play in HNSCC etiology, researchers found that detection of β1-HPV-5 type was associated with oropharyngeal (OR, 7.42; 95% CI: 0.98-56.82; P =.054), oral cavity (OR, 5.34; 95% CI: 1.51-18.80; P =.01), and laryngeal SCCs (OR, 2.71; 95% CI: 1.00-7.43; P =.05).

The study further demonstrated that γ11- and γ12-HPV types were associated with both oral cavity (OR, 7.47; 95% CI: 1.21-46.17; P .03; and OR, 6.71; 95% CI: 1.47-30.75; P =.01, respectively) and laryngeal SCCs (OR, 7.49; 95% CI, 1.10-51.04; P = .04 and OR, 5.31; 95% CI, 1.13-24.95; P =.03, respectively).

REFERENCE

1. Agalliu I, Gapstur S, Chen Z, et al. Associations of oral α-, β-, and γ-human papillomavirus types with risk of incident head and neck cancer [published online ahead of print January 21, 2016]. JAMA Oncology. doi:10.1001/jamaoncol.2015.5504.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs